ORMP Valuation

Oramed Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.110

-0.020(-0.940%)

Overview
Forecast
Valuation

ORMP Relative Valuation

ORMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ORMP is overvalued; if below, it's undervalued.

Historical Valuation

Oramed Pharmaceuticals Inc (ORMP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 83.02. The fair price of Oramed Pharmaceuticals Inc (ORMP) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.11 USD , Oramed Pharmaceuticals Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：2.11

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.58

P/B

Median3y

0.94

Median5y

2.15

-9.69

FCF Yield

Median3y

-13.96

Median5y

-12.47

Competitors Valuation Multiple

The average P/S ratio for ORMP's competitors is 0.34, providing a benchmark for relative valuation. Oramed Pharmaceuticals Inc Corp (ORMP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

ORMP.O

Oramed Pharmaceuticals Inc

Loss

Average P/S: 0.34

86.19M